Number of Participants with Unsolicited Adverse Events;Number of Participants with Serious Adverse Events (SAEs);2-fold and 4-fold Rise in Neutralization Antibody titer at Day 36;Percentage of Participants with Neutralizing Antibody Seroconversion at Day 36;Percentage of Participants with Neutralizing Antibody Seroconversion at Day 22;Number of Participants with Immediate Adverse Events;2-fold and 4-fold Rise in Neutralization Antibody titer at Day 22;Number of Participants With Solicited Injection Site or Systemic Reactions;Number of Participants with Out-of-range Biological Test Results;Neutralizing Antibody Titer at Day 22;Fold-rise of Neutralizing Antibody Titer at Day 36;Number of Participants with Adverse Events of Special Interest;Neutralizing Antibody Titer at Day 1;Fold-rise of Neutralizing Antibody Titer at Day 22;Number of Participants with Medically Attended Adverse Events;Neutralizing Antibody Titer at Day 36

Number of Participants with Unsolicited Adverse Events;Number of Participants with Serious Adverse Events (SAEs);2-fold and 4-fold Rise in Neutralization Antibody titer at Day 36;Percentage of Participants with Neutralizing Antibody Seroconversion at Day 36;Percentage of Participants with Neutralizing Antibody Seroconversion at Day 22;Number of Participants with Immediate Adverse Events;2-fold and 4-fold Rise in Neutralization Antibody titer at Day 22;Number of Participants With Solicited Injection Site or Systemic Reactions;Number of Participants with Out-of-range Biological Test Results;Neutralizing Antibody Titer at Day 22;Fold-rise of Neutralizing Antibody Titer at Day 36;Number of Participants with Adverse Events of Special Interest;Neutralizing Antibody Titer at Day 1;Fold-rise of Neutralizing Antibody Titer at Day 22;Number of Participants with Medically Attended Adverse Events;Neutralizing Antibody Titer at Day 36